Refractory celiac disease: what it is, how rare it is and how it is diagnosed
Short answer
Refractory celiac disease is a rare condition3 in which symptoms and villous atrophy persist despite at least 12 months of strict gluten-free diet1. The AGA advises strongly considering it after other more common causes and malignancy have been excluded20. Ongoing symptoms have many other possible causes, and gluten ingestion is the most common one13. Two types are recognized, and they differ in outlook25.
Part of Symptoms, reactions and persistent complaints, 22 guides

Key points
- Refractory celiac disease means persistent symptoms and villous atrophy despite at least 12 months of strict gluten-free diet, in the AGA's definition1.
- Gluten ingestion is the most common cause of non-responsive celiac disease, so it is checked first13, 18.
- It is rare, but sources differ on how rare: approximately 1% (AGA)8, 1–2% (ACG)7, around 0.3 to 4.0% (Coeliac UK)10. Coeliac UK says it is thought to be over diagnosed11.
- Type 2 has an aberrant, clonal IEL population24 and a poorer prognosis than type 125.
- The AGA says no FDA-approved therapies exist; steroids are first-line in either type33, 41.
What refractory celiac disease is
The American Gastroenterological Association (AGA) defines refractory celiac disease (RCD) as celiac disease with persistent symptoms of malabsorption and villous atrophy despite at least 12 months of strict adherence to a gluten-free diet1. The AGA adds that persistent villous atrophy is necessary but not sufficient for the diagnosis2.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes it as a rare condition in which symptoms and damage to the small intestine continue or come back even while a person is following a strict gluten-free diet3. The NIDDK says it may lead to complications such as malnutrition or a type of cancer called enteropathy-associated T-cell lymphoma (EATL)4.
The AGA lists the symptoms and signs that could raise suspicion of RCD as diarrhea, weight loss, anemia, and malabsorption with persistent nutritional deficiencies5. The sections below cover the causes doctors check first.
Refractory is not the same as non-responsive. The American College of Gastroenterology (ACG) defines non-responsive celiac disease as persistent symptoms, signs or laboratory abnormalities typical of celiac disease despite 6 to 12 months of dietary gluten avoidance6. Refractory disease is one possible cause of that picture13. See our guide to non-responsive celiac disease.
How rare is it?
The sources do not give one figure. Each is an estimate of the share of people with celiac disease who have RCD:
| Source | What it says |
|---|---|
| ACG guideline (2013) | Uncommon, affecting 1–2% of patients with celiac disease7 |
| AGA clinical practice update (2022) | Approximately 1%, although the authors say this may be an overestimate, as data are obtained from referral centers8 |
| Coeliac UK (for the public) | Between 4 in 100 and 3 in 1,000 people with coeliac disease9 |
| Coeliac UK (for healthcare professionals) | Around 0.3 to 4.0%, with the true prevalence unknown10 |
Coeliac UK says refractory disease is thought to be over diagnosed, because it can be difficult to tell true refractory disease from celiac disease where gluten is still getting into the diet11.
Coeliac UK also says it is extremely rare in people under 30 and that most people with it are diagnosed over the age of 5012.
Why other causes are checked first
The ACG lists many causes of non-responsive celiac disease: inadvertent gluten ingestion (the most common), other food intolerances including lactose and fructose intolerance, small intestinal bacterial overgrowth, microscopic colitis, pancreatic insufficiency, irritable bowel syndrome and refractory celiac disease13.
For gluten, the ACG says ingestion, purposeful or inadvertent, was identified in 35% to 50% of cases of non-responsive disease14. The AGA puts persistent gluten ingestion at 40%–50% of patients with poorly or nonresponsive celiac disease15.
The AGA also notes that negative serologies do not completely exclude intermittent or low-level gluten ingestion, and that celiac antibody levels are often normal in patients with RCD16.
Our guides to still symptomatic on a gluten-free diet and non-responsive celiac disease cover these causes, and the celiac blood test guide covers the antibody tests.
How doctors reach the diagnosis
The AGA advises considering refractory celiac disease after other more common causes and malignancy are excluded20, and a 2024 review calls type 1 a diagnosis of exclusion60. The AGA's best-practice advice runs in this order:
- Confirm the original celiac disease diagnosis by reviewing the prior serologies, endoscopies and histologic findings17.
- Exclude ongoing gluten ingestion with serologic testing, dietitian review, and detection of immunogenic peptides in stool or urine, and perform endoscopy with small bowel biopsies to look for villous atrophy18.
- If villous atrophy persists or the original diagnosis was not confirmed, consider other causes of villous atrophy: common variable immunodeficiency, autoimmune enteropathy, tropical sprue and medication-induced enteropathy18.
- After gluten is excluded, evaluate systematically for functional bowel disorders, microscopic colitis, pancreatic insufficiency, inflammatory bowel disease, lactose or fructose intolerance and small intestinal bacterial overgrowth19.
- Consider RCD strongly when symptoms or signs of malabsorption persist after the more common causes and malignancy have been excluded20.
The British Society of Gastroenterology (BSG) also recommends a follow-up biopsy for patients with persistent symptoms despite a gluten-free diet21. The ACG says normal or near-normal small intestinal histology suggests other causes, such as irritable bowel syndrome, microscopic colitis, food intolerances or pancreatic insufficiency22. Our guide to repeat biopsy and mucosal healing covers the biopsy step.
The authors of the AGA update say that diagnosis and management remain challenging because of the rarity of the condition and the absence of a reference standard diagnostic marker23.
Type 1 and type 2: what separates them
The AGA divides RCD into two types by the intraepithelial lymphocytes (IELs) found on biopsy: a normal IEL population in type 1 and an aberrant, clonal one in type 224.
| Type 1 | Type 2 | |
|---|---|---|
| The cells | A normal IEL population, similar to that in conventional celiac disease25, 26 | An aberrant, clonal IEL population24; the ACG describes an abnormal immunophenotype lacking normal surface markers such as CD827 |
| Outlook | The BSG describes a good prognosis28 | A poorer prognosis, due predominantly to nutritional complications and transformation into EATL (BSG)28 |
| Lymphoma | The AGA says the risk of lymphoma is extremely low29 | Implies risk of ulcerative jejunoileitis or EATL25; one 2024 review calls it a low-grade intraepithelial lymphoma30 |
| Survival in one study cited by the ACG | 5-year survival of 93%31 | 5-year survival of 44%31 |
The ACG says Type I appears to be more common than Type II in the United States32.
Read the survival figures with care: they come from one study31, and the BSG notes that the criteria used to diagnose type 2 vary34.
Tests a specialist uses
To tell the types apart, and to look for lymphoma, the AGA advises flow cytometry, immunohistochemistry and T-cell receptor rearrangement studies, with an expert hematopathologist to interpret them24.
The BSG says the most important aspect of separating the types is showing a monoclonal population of T cells or aberrant T cells in type 235. The AGA cautions that a type 2 diagnosis cannot rest on clonal T-cell receptor rearrangements alone, because clones can be detected with newly diagnosed celiac disease, celiac disease on a gluten-free diet, and type 136.
At the first diagnosis of type 2, the AGA advises small bowel imaging with capsule endoscopy and computed tomography or magnetic resonance enterography, to exclude EATL and ulcerative jejunoileitis37. For type 1 it says imaging is indicated only if the person is not doing well on therapy29.
The AGA also advises a detailed nutritional assessment for micronutrient and macronutrient deficiencies, and checking albumin as an independent prognostic factor38.
In the UK, Coeliac UK says the specific diagnostic test is only available through specialist centres in Sheffield and Cambridge39.
What treatment and monitoring involve
The AGA says there are no US Food and Drug Administration–approved therapies, and that its management suggestions rest on small retrospective studies and expert opinion33. The BSG likewise says there is no standard treatment40.
The AGA advises corticosteroids, most commonly open-capsule budesonide or, if unavailable, prednisone, as first-line therapy in either type41. It reports that overall 80%–90% of patients have an adequate clinical response to open-capsule budesonide or prednisone, higher in type 142.
Beyond first-line steroids, the ACG says, in its section on type I, that when the response to steroids is incomplete or symptoms recur as the dose is reduced, immunosuppressive agents such as azathioprine can be used43. The AGA says the best treatment for type 2 is unknown and that a reduction of lymphoma risk with steroids has not been proven in prospective studies44, and it says immunosuppressants are not advised in type 2 because of concern about accelerated lymphoma development, although data are scarce45.
For nutrition, the AGA advises correcting deficiencies with oral supplements and/or enteral support, and considering parenteral nutrition for severe malnutrition due to malabsorption46.
The gluten-free diet continues. Beyond Celiac states that anyone with celiac disease, no matter what type, must remain on a strict gluten-free diet for the rest of their life47. Coeliac UK says support from a dietitian is required to stay on the diet and get the nutrients needed48.
Follow-up
The AGA says patients with RCD require regular follow-up by a multidisciplinary team including gastroenterologists and dietitians to assess clinical and histologic response49. It notes that this follow-up is based on expert opinion50. Its authors advise a repeat intestinal biopsy 3–6 months after starting therapy51, and report that mucosal recovery has been demonstrated in type 1 but is less likely in type 252. The dietitian's role in that follow-up includes malnutrition management, assessment of adherence and continuing a strict gluten-free diet53.
Where specialist care comes from
The AGA says patients with RCD who do not respond to steroids may benefit from referral to a center with expertise, or from evaluation for inclusion in clinical trials54. The BSG recommends that patients with RCD be referred to a tertiary centre55.
In the UK, the NHS has approved specialist teams in Sheffield and Cambridge as a Rare Disease Collaborative Network for difficult cases of non-responsive or refractory coeliac disease56.
In the US, the AGA advises identifying local experts with expertise in celiac disease49. The Celiac Disease Foundation's free practitioner directory flags practitioners who take part in its Celiac Disease Recognized Unit of Excellence (CRUE) program or have demonstrated continuing education in celiac disease57.
The NIDDK's advice for continuing symptoms on a gluten-free diet is to talk with a doctor or a registered dietitian, who can help find the cause58.
Questions people ask
Does a normal celiac blood test rule out refractory celiac disease?
The AGA says celiac antibody levels are often normal in patients with RCD, and that negative serologies do not completely exclude intermittent or low-level gluten ingestion16.
Is refractory celiac disease cancer?
Type 2 is regarded by the AGA authors as a low-grade or intraepithelial malignancy, with progression to full-blown EATL marked by large or atypical lymphocytes and discrete tumors59. For type 1, the AGA says the risk of lymphoma is extremely low29.
Do children get refractory celiac disease?
Coeliac UK says it is extremely rare in people under 30 years of age12.
Is there an approved medicine for it?
The AGA says there are no US Food and Drug Administration–approved therapies; treatment suggestions are based on small retrospective studies and expert opinion33.
More in Symptoms, reactions and persistent complaints
Non-responsive celiac disease: what clinicians check, and in what orderWhat guidelines say clinicians check when celiac disease does not settle on the diet: gluten exposure, antibodies, biopsy, other causes.
Still tired on a gluten-free diet: the causes clinicians checkWhy fatigue can continue on a gluten-free diet: gluten exposure, other gut conditions, iron, B12, thyroid, sleep, mood, and follow-up lists.
Celiac disease symptoms in adults: what the sources list and who gets testedDigestive and non-digestive celiac symptoms as NIDDK, ACG and Coeliac UK list them, who guidelines say to test, and why gluten stays in the diet first.
Celiac disease and migraines: what studies report and how strong the evidence isWhat studies report about migraine and headache in celiac disease, how strong that evidence is, and where to read a medicine’s inactive ingredients.
Numbness and tingling in celiac disease: what studies show and what else is on the listWhat studies report on numbness and tingling in celiac disease, how B12 and other causes fit, and where celiac testing sits in a nerve work-up.
Joint pain and celiac disease: what the research documents and what it does notWhat studies report on joint pain in celiac disease, how strong each link is, why the rheumatoid arthritis evidence is mixed, and other causes.
All 22 guides in Symptoms, reactions and persistent complaints
Related guides
Still having symptoms on a gluten-free diet? Where gluten can still get inA checklist of label, kitchen, restaurant, product and medicine sources of gluten, and what the sources say about when to see a doctor.
Celiac Blood Tests: What tTG-IgA, Total IgA, DGP and EMA Each CheckWhat tTG-IgA, total IgA, EMA and DGP check, why total IgA is drawn with tTG-IgA, when back-up tests are used, and why gluten stays in the diet first.
The repeat biopsy in celiac disease: when guidelines suggest one and what the result meansWhen guidelines suggest a repeat biopsy in celiac disease, what Marsh grades on the report mean, and what the guidelines say follows if damage persists.
Celiac disease complications and cancer risk: how to read the numbersWhat NIDDK, Coeliac UK, a 2025 European guideline and Swedish cohort studies report on celiac disease complications and cancer, relative next to absolute.
Sources
- [1, 2, 5, 8, 15, 16, 17, 18, 19, 20, 23, 24, 25, 29, 33, 36, 37, 38, 41, 42, 44, 45, 46, 49, 50, 51, 52, 53, 54, 59] American Gastroenterological Association (Gastroenterology), AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review (2022), checked Nov 17, 2026.
- [3, 4, 58] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Treatment for Celiac Disease, checked Nov 17, 2026.
- [6, 7, 13, 14, 22, 26, 27, 31, 32, 43] American College of Gastroenterology (Am J Gastroenterol), ACG Clinical Guidelines: Diagnosis and Management of Celiac Disease (2013), checked Nov 17, 2026.
- [9, 11, 12, 39, 48] Coeliac UK, Non responsive and refractory coeliac disease, checked Nov 17, 2026.
- [10, 56] Coeliac UK, Ongoing symptoms and complications (for healthcare professionals), checked Nov 17, 2026.
- [21, 28, 34, 35, 40, 55] British Society of Gastroenterology (Gut), Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology (2014), checked Nov 17, 2026.
- [30, 60] PubMed (Gastroenterology), Advances in Nonresponsive and Refractory Celiac Disease (2024), checked Nov 17, 2026.
- [47] Beyond Celiac, Non-Responsive and Refractory Celiac Disease, checked Nov 17, 2026.
- [57] Celiac Disease Foundation, Find a Healthcare Practitioner, checked Nov 17, 2026.